CC-LP-1Homo sapiens (Human)Cancer cell line
Also known as: CCLP1, CCLP-1, CC-LP-I
🤖 AI SummaryBased on 1 publications
Quick Overview
Human cell line with IDH mutations showing dasatinib hypersensitivity.
Detailed Summary
CC-LP-1 is a human cell line with known isocitrate dehydrogenase (IDH) mutations, which confer hypersensitivity to the multi-kinase inhibitor dasatinib. Research indicates that IDH mutant (IDHm) intrahepatic cholangiocarcinoma (ICC) cells exhibit a unique dependency on SRC signaling, making them highly responsive to dasatinib. This cell line is used in studies to explore the therapeutic potential of targeting SRC in IDHm ICC, with evidence showing that SRC inhibition leads to significant cytotoxicity in these cells. The cell line has been utilized in high-throughput drug screens and in vivo xenograft models to evaluate drug efficacy and mechanisms of action.
Research Applications
Dasatinib hypersensitivitySRC-dependence in IDH mutant ICCHigh-throughput drug screeningIn vivo xenograft models
Key Characteristics
IDH mutationsDasatinib sensitivitySRC signaling dependency
Generated on 6/15/2025
Basic Information
| Database ID | CVCL_0205 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Liver[UBERON:UBERON_0002107] |
Donor Information
| Age | 48 |
|---|---|
| Age Category | Adult |
| Sex | Male |
Disease Information
| Disease | Cholangiocarcinoma |
|---|---|
| Lineage | Biliary Tract |
| Subtype | Intrahepatic Cholangiocarcinoma |
| OncoTree Code | IHCH |
DepMap Information
| Source Type | Academic lab |
|---|---|
| Source ID | ACH-001959_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Arg306Ter (c.916C>T) | Heterozygous | Germline | PubMed=16418264 |
| MutationSimple | CTNNB1 | p.Gly34Val (c.101G>T) | Unspecified | - | Unknown |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Amelogenin
X,Y
CSF1PO
11,13
D13S317
9,12
D16S539
9,13
D18S51
13,14
D21S11
29,33
D3S1358
15,16
D5S818
11,12
D7S820
10,11
D8S1179
11,13
FGA
22
Penta D
12,13
Penta E
12
TH01
9.3
TPOX
8,11
vWA
15,17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines
Loading gene expression data...
Publications
Generation of a biliary tract cancer cell line atlas reveals molecular subtypes and therapeutic targets.
Vazquez F., Getz G., Bardeesy N.M.
bioRxiv 2024:07.04.601970-07.04.601970(2024).
Development and characterization of human primary cholangiocarcinoma cell lines.
Glaser S., Kennedy L., Francis H., Zhang W.-J., Alpini G.D., Ekser B.
Am. J. Pathol. 192:1200-1217(2022).
TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma.
Zhu A.X.-X., Corcoran R.B., Bardeesy N.M.
Cancer Discov. 9:1064-1079(2019).
Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma.
Bardeesy N.M.
Cancer Discov. 6:727-739(2016).